Polysubstance Overdoses and ICU Demand: What Hospitals Should Watch Next

Back to Telehealth Blog

 July 17, 2026

A changing illicit drug supply is creating new challenges for emergency departments and ICUs. While fentanyl remains central to many overdose emergencies, emerging adulterants such as medetomidine are making patient presentations more complex, less predictable, and more resource-intensive.

For hospitals, especially community and rural facilities, this is no longer only an emergency department issue. Increasingly complex polysubstance overdoses can create downstream pressure on ICU teams, respiratory support, specialty consultation, and nursing resources.

A more complicated overdose picture

Overdose care has historically focused heavily on opioid reversal and respiratory stabilization. That remains essential, but the illicit drug supply has changed. Fentanyl may be mixed with other substances, including benzodiazepines, xylazine, medetomidine, stimulants, and emerging synthetic opioids.

These combinations can complicate care in several ways. Patients may present with profound sedation, respiratory depression, bradycardia, hypotension or hypertension, altered mental status, agitation, wounds, withdrawal symptoms, or mixed clinical pictures that are difficult to quickly identify. In some cases, naloxone remains necessary because fentanyl may be involved, but it may not resolve the full clinical picture when non-opioid sedatives or other adulterants are also present.

That matters for hospitals because these patients may require prolonged monitoring, airway management, hemodynamic support, wound care, withdrawal management, and ICU-level observation.

Medetomidine adds a new concern

For the last several years, xylazine, often referred to as “tranq,” has received significant attention as a dangerous adulterant in the fentanyl supply. More recently, in some markets, medetomidine has emerged as a growing concern alongside or in place of xylazine.

Medetomidine is a veterinary sedative that is not approved for human use. Public health agencies have linked it to severe sedation, low heart rate, and complex withdrawal concerns. In clinical settings, this can create a more complicated care pathway, particularly when patients do not respond as expected to standard overdose interventions.

This is not a reason to abandon established overdose protocols. Rather, it is a reason for hospital teams to recognize that today’s overdose patients may require broader assessment, careful monitoring, and rapid escalation when symptoms persist or worsen.

The ICU implications

For ICU leaders, the challenge is not just the number of overdose cases. It is the intensity and unpredictability of those cases.

A patient who initially appears stable may deteriorate. A patient who responds partially to naloxone may still have persistent sedation or other complications. A patient with polysubstance exposure may need respiratory support, aggressive monitoring, or management of severe withdrawal. In hospitals with limited specialty coverage, the need for toxicology, critical care, pharmacy, behavioral health, wound care, and respiratory expertise can quickly exceed available resources.

This can extend length of stay, increase staffing strain, and complicate ED-to-ICU decision-making. It may also increase transfers, particularly when community or rural hospitals do not have immediate access to intensivists or other specialists.

Why escalation pathways matter

In complex overdose care, timing is everything. Hospitals need clear pathways for recognizing when a patient requires ICU-level support, when specialty input is needed, and when transfer should be considered.

Key operational questions include:

  • Are ED and ICU teams aligned on escalation criteria for complex overdose presentations?
  • Is there rapid access to critical care consultation after hours?
  • Are teams prepared for prolonged sedation or severe withdrawal symptoms?
  • Are respiratory therapy, pharmacy, and nursing teams equipped for higher-acuity monitoring?
  • Are transfer pathways reliable when local ICU capacity or specialty access is limited?  

These questions are especially important for hospitals that serve rural or underserved regions, where substance-use patterns may change quickly, but specialist access may be limited.

Building resilience into the care model

Hospitals cannot control the composition of the illicit drug supply. They can, however, strengthen the systems that help teams respond.

That includes maintaining flexible critical care coverage, supporting bedside teams with timely specialist input, standardizing escalation pathways, and ensuring that ED-to-ICU transitions are efficient and clinically informed.

Virtual critical care can be one part of that broader response. By giving bedside teams access to experienced intensivists and critical care support, hospitals can improve consistency in decision-making, especially when patient presentations are complex and local resources are stretched.

Looking ahead

Polysubstance overdoses are likely to remain unpredictable. As new adulterants enter the drug supply, hospitals will need to prepare not only for higher volume but for higher complexity.

For ICU and hospital leaders, the priority is clear: build systems that support rapid recognition, timely escalation, and consistent access to critical care expertise when patients deteriorate.

To learn how Intercept Telehealth helps hospitals strengthen ICU readiness with 24/7 virtual critical care support, contact our team.